Table 11.
Generalized | Drug-resistant patients (N = 42) | Drug-responsive patients (N = 33) | ORs | 95% CI | p value | X 2 | |||
n | % | n | % | ||||||
ABCB1 C1236T genotypes | TT vs. CC+CT | 23 | 54.762 | 2 | 6.061 | 18.763 | 3.968-88.729 | ≤0.001 | 19.720 |
TT vs. CC | 23 | 82.143 | 2 | 14.286 | 27.600 | 4.644-164.027 | ≤0.001 | 17.840 | |
ABCB1 G2677T genotypes | TT vs. GG+GT | 24 | 57.143 | 4 | 12.121 | 7.250 | 2.209-23.800 | 0.001 | 12.410 |
TT vs. GT | 24 | 68.571 | 4 | 12.903 | 14.727 | 4.137-52.423 | ≤0.001 | 20.860 | |
ABCB1 C3435T genotypes | TT vs. CC+CT | 26 | 61.905 | 3 | 9.091 | 16.250 | 4.254-62.079 | ≤0.001 | 21.740 |
TT vs. CC | 26 | 72.222 | 3 | 16.667 | 13.000 | 3.086-54.773 | 0.001 | 14.900 | |
TT vs. CT | 26 | 81.250 | 3 | 16.667 | 21.667 | 4.717-99.530 | ≤0.001 | 19.720 | |
ABCB1 C1236T alleles | TT vs. CT | 23 | 61.162 | 2 | 9.524 | 15.607 | 3.147-77.409 | 0.001 | 15.140 |
T vs. C | 60 | 71.429 | 23 | 34.848 | 4.674 | 2.337-9.348 | ≤0.001 | 20.010 | |
ABCB1 G2677T alleles | T vs. G | 59 | 70.238 | 35 | 53.030 | 2.090 | 1.067-4.096 | 0.032 | 4.680 |
ABCB1 C1236T-G2677T | TG | 9 | 21.429 | 1 | 3.030 | 8.727 | 1.045-72.888 | 0.045 | 5.410 |
TT | 14 | 33.333 | 1 | 3.030 | 16.000 | 1.977-129.518 | 0.009 | 10.610 | |
ABCB1 G2677T-C3435T | GT | 13 | 30.952 | 3 | 9.091 | 4.483 | 1.156-17.382 | 0.030 | 5.260 |
TT | 12 | 28.571 | 0 | 0 | 27.459 | 1.559-483.811 | 0.024 | 11.220 | |
ABCB1 C1236T-C3435T | TC | 10 | 23.810 | 2 | 6.061 | 4.844 | 0.981-23.908 | 0.053 | 4.330 |
TT | 13 | 30.952 | 0 | 0 | 30.661 | 1.746-538.489 | 0.019 | 12.360 | |
| |||||||||
Focal | Drug-resistant patients (N = 3) | Drug-responsive patients (N = 17) | ORs | 95% CI | p value | X 2 | |||
n | % | n | % | ||||||
ABCB1 C3435T alleles | T vs. C | 5 | 83.333 | 11 | 32.353 | 10.455 | 1.087-100.599 | 0.042 | 5.520 |
ABCB1 C1236T-C3435T | CT | 2 | 66.667 | 1 | 5.882 | 32.000 | 1.389-737.501 | 0.030 | 7.390 |
Values (n and %). ORs: odds ratio; 95% CI: confidence interval; significant p value ≤ 0.05; X2: chi-square.